MedTrace Logo

Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients

NCT05106491 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-03-14

No results posted yet for this study

Summary

The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4

Conditions

  • Cardiogenic Shock
  • Extracorporeal Membrane Oxygenation
  • ECLS
  • VA ECMO

Interventions

DEVICE

Synchronized Cardiac Support with the icor kit

Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).

Sponsors & Collaborators

  • Xenios AG

    lead INDUSTRY

Principal Investigators

  • Ingo Voigt, Dr. · Elisabeth-Krankenhaus Essen

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05106491 on ClinicalTrials.gov